Whitehawk Therapeutics, INC. (WHWK) — 10-Q Filings

10-Q Filings (6)

• Whitehawk Soars to Profit on FYARRO Sale, Pivots to ADC Pipeline — Nov 6, 2025 Risk: high
  Whitehawk Therapeutics, Inc. (WHWK) reported a significant strategic shift and financial turnaround for the nine months ended September 30, 2025. The company po
• Whitehawk Boosts Revenue Amidst High R&D Spend — Aug 7, 2025 Risk: medium
  Whitehawk Therapeutics, Inc. reported product revenue of $10.2 million for the three months ended June 30, 2025, and $19.8 million for the six months ended June
• Whitehawk Therapeutics Files Q1 2025 10-Q — May 8, 2025 Risk: medium
  Whitehawk Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Aadi Bioscience, Inc., is in the pharmaceutical
• Aadi Bioscience Files Q3 2024 10-Q — Nov 6, 2024 Risk: medium
  Aadi Bioscience, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results for the third quarter and the first nine m
• Aadi Bioscience Files Q2 2024 10-Q — Aug 7, 2024 Risk: medium
  Aadi Bioscience, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results for the second quarter and the first half of 20
• Aadi Bioscience Files 10-Q for Period Ending March 31, 2024 — May 8, 2024 Risk:
  Aadi Bioscience, Inc. (WHWK) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Aadi Bioscience reported $0 in revenue for Q1 2024, a decrease from $0

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX